Several new-generation MDM2 inhibitors have been developed, including RG7388 [32], HDM201 [33], AMG232 [34], DS-3032 [35], ASTX295 [36], and MI-77301 [37], which have been shown to reduce cancer cell viability and proliferation in preclinical models, including leukemia and lymphoma cells [38,39,40,41,42,43,44]. Here, MDM2 is linked to cancer.